May 26, 2021 -- GNS Healthcare has announced plans to develop and launch an in silico digital patient called Gemini to help determine responses to treatment for developers of prostate cancer drugs.
GNS said Gemini will link drug treatment to patient characteristics and to the genetic and molecular mechanisms and pathways driving clinical outcomes. This will enable the simulation of disease progression and drug response at an individual patient level.
Gemini will leverage the Lens platform, a cloud-based data and analytics platform launched in May by Tempus. The Lens platform provides on-demand access to Tempus' library of deidentified clinical and molecular data, along with artificial intelligence analytical tools for drug discovery and development.